NBIX vs. BMY
Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBIX or BMY.
Correlation
The correlation between NBIX and BMY is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NBIX vs. BMY - Performance Comparison
Key characteristics
NBIX:
0.39
BMY:
0.57
NBIX:
0.71
BMY:
1.11
NBIX:
1.11
BMY:
1.14
NBIX:
0.48
BMY:
0.34
NBIX:
1.05
BMY:
1.41
NBIX:
12.29%
BMY:
11.55%
NBIX:
33.38%
BMY:
28.56%
NBIX:
-97.21%
BMY:
-70.62%
NBIX:
-11.56%
BMY:
-23.77%
Fundamentals
NBIX:
$13.84B
BMY:
$116.92B
NBIX:
$3.75
BMY:
-$3.58
NBIX:
0.32
BMY:
1.92
NBIX:
$2.24B
BMY:
$47.44B
NBIX:
$2.20B
BMY:
$33.40B
NBIX:
$614.00M
BMY:
$5.06B
Returns By Period
In the year-to-date period, NBIX achieves a 2.80% return, which is significantly lower than BMY's 16.38% return. Over the past 10 years, NBIX has outperformed BMY with an annualized return of 18.69%, while BMY has yielded a comparatively lower 2.39% annualized return.
NBIX
2.80%
15.16%
3.51%
11.48%
4.30%
18.69%
BMY
16.38%
0.07%
42.98%
14.59%
1.32%
2.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NBIX vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NBIX vs. BMY - Dividend Comparison
NBIX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.22%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.22% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
NBIX vs. BMY - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NBIX and BMY. For additional features, visit the drawdowns tool.
Volatility
NBIX vs. BMY - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 7.24% compared to Bristol-Myers Squibb Company (BMY) at 6.37%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NBIX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities